RealWorld Dynamix™: Biologic Switching in IBD 2017

According to RealWorld Dynamix: Biologic Switching in IBD, an annual patient chart analysis conducted by Spherix Global Insights, biologic use in IBD is becoming increasingly dynamic, with switching rates up significantly in both ulcerative colitis (UC) and Crohn’s disease (CD) compared to 2016. Furthermore, switching patterns have changed dramatically with the recent introduction of Stelara.

Click on the button below to download highlights from this report.

RWD: Biologic and Otezla Switching in PsA

2017-06-18T12:58:38+00:00